维多利亚老品牌76696vic-在线入口

專注提供質高價優

的生物藥

科學論文

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study[J]. BioDrugs, 2021:1-14.
BioDrugs
Hou, MM., Ho, CL., Lin, HY. et al. Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers. Invest New Drugs (2021). https://doi.org/10.1007/s10637-021-01099-1
Invest New Drugs
Xu, B., Zhang, Q., Sun, T. et al. Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial. BioDrugs(2021). https://doi.org/10.1007/s40259-021-00475-w.
Biodrugs
Zhang H, Wu M, Sun J, Zhu X, Li C, Ding Y, Zhang X, Chai K, Li X. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study. Pharmacol Res Perspect. 2021 Apr; 9(2):e00733. doi: 10.1002/prp2.733.
Pharmacol Res Perspect
Shi, Y., Song, Y., Qin, Y. et al. A phase 3 study of rituximab biosimilar HLX01 in patients with diffuse la